top of page

Process
Technology
Partnerships
Case Studies & Pipeline
News
Contact
About
More

Use tab to navigate through the menu items.

Qubigen data representation

News

Subscribe to Newsletter

Qubigen Successfully Completes Initial Testing of Generative AI for Molecular Candidates

Qubigen Successfully Completes Initial Testing of Generative AI for Molecular Candidates

Qubigen Successfully Completes Initial Testing of Generative AI for Molecular Candidates

Qubigen is excited to announce the successful completion of our initial research project which used Generative AI to accelerate novel...

Dec 31, 20242 min read

Qubigen Secures Strategic Pre-Seed Investment from SYNthesis BioVentures to Advance Federated AI Drug Design

Qubigen Secures Strategic Pre-Seed Investment from SYNthesis BioVentures to Advance Federated AI Drug Design

Qubigen Secures Strategic Pre-Seed Investment from SYNthesis BioVentures to Advance Federated AI Drug Design

Qubigen Pty Ltd is proud to announce that it has secured its first tranche of pre-seed equity funding from SYNthesis BioVentures through...

Dec 5, 20242 min read

Presagen co-founder forms new AI-powered drug discovery company

Presagen co-founder forms new AI-powered drug discovery company

Presagen co-founder forms new AI-powered drug discovery company

Hot on the heels of selling Life Whisperer to a Japanese IVF firm, a co-founder of Adelaide-based health tech Presagen has created a new...

Dec 2, 20241 min read

enquiries@qubigen.com

Bio21 Institute

30 Flemington Road

Parkville VIC 3052

Australia

Accelerate drug design
without exposing secrets

Connect with Us

© 2025 Qubigen. All rights reserved.

bottom of page